PAR logo

Paradigm Biopharmaceuticals Limited Stock Price

ASX:PAR Community·AU$156.5m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 23 Fair Values set on narratives written by author
Create a narrative

PAR Share Price Performance

AU$0.38
0.17 (80.95%)
93.1% undervalued intrinsic discount
AU$5.50
Fair Value
AU$0.38
0.17 (80.95%)
93.1% undervalued intrinsic discount
AU$5.50
Fair Value
Price AU$0.38
AmirV AU$5.50

PAR Community Narratives

AmirV·
Fair Value AU$5.5 93.1% undervalued intrinsic discount

Paradigm Biopharmaceuticals Will Lead Osteoarthritis Treatment with Zilosul's FDA Success

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative

Recent PAR News & Updates

Paradigm Biopharmaceuticals Will Lead Osteoarthritis Treatment with Zilosul's FDA Success

Paradigm Biopharmaceuticals (ASX: PAR) on Cusp of Transformation with Potential FDA Approval of Osteoarthritis Drug Zilosul® Melbourne, Australia - Paradigm Biopharmaceuticals (ASX: PAR), a late-stage drug development company, is poised at a critical juncture as it progresses its lead drug candidate, Zilosul® (injectable pentosan polysulfate sodium), through Phase 3 clinical trials for the treatment of osteoarthritis (OA). A successful outcome and subsequent clearance from the U.S. Food and Drug Administration (FDA) could unlock a multi-billion dollar market and fundamentally reshape the company's future, offering a new treatment paradigm for millions suffering from the debilitating joint disease.

We're Keeping An Eye On Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Rate

Apr 22
We're Keeping An Eye On Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Rate

Paradigm Biopharmaceuticals Limited Key Details

AU$0

Revenue

AU$20.6k

Cost of Revenue

-AU$20.6k

Gross Profit

AU$18.8m

Other Expenses

-AU$18.8m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.046
Gross Margin
0%
Net Profit Margin
0%
Debt/Equity Ratio
0%

Paradigm Biopharmaceuticals Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

2 Risks
2 Rewards
View Full Analysis

About PAR

Founded
2014
Employees
n/a
CEO
Paul Rennie
WebsiteView website
www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

Market Insight

Header cover image

📈 Markets Break Records: Q3 2025 in Review, Q4 Outlook Ahead

Richard Bowman avatarRichard Bowman
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Last Week
✨Rare Earths: Tiny Market, Outsized Influence

✨Rare Earths: Tiny Market, Outsized Influence

Australian Market Performance

  • 7 Days: -0.2%
  • 3 Months: 5.3%
  • 1 Year: 8.9%
  • Year to Date: 9.5%
In the last week, the market has been flat. More promisingly, the market is up 8.9% over the past year. Earnings are forecast to grow by 12% annually. Market details ›